Q4 EPS Estimate for Puma Biotechnology Boosted by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Investment analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for Puma Biotechnology in a research report issued to clients and investors on Wednesday, January 22nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.16 per share for the quarter, up from their previous forecast of $0.13. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Several other brokerages also recently commented on PBYI. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday, December 23rd.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI opened at $3.02 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The stock has a market cap of $148.25 million, a PE ratio of 6.29 and a beta of 1.10. The stock has a fifty day moving average of $3.05 and a 200-day moving average of $2.99.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. During the same period last year, the firm earned $0.12 EPS.

Insider Buying and Selling

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now owns 108,951 shares of the company’s stock, valued at $343,195.65. This trade represents a 7.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the transaction, the chief executive officer now directly owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. The trade was a 0.48 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Puma Biotechnology

Several hedge funds have recently added to or reduced their stakes in PBYI. American Century Companies Inc. boosted its stake in Puma Biotechnology by 98.5% in the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after buying an additional 366,653 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after purchasing an additional 246,264 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Puma Biotechnology during the 3rd quarter valued at $627,000. Advantage Alpha Capital Partners LP purchased a new position in Puma Biotechnology in the 3rd quarter worth $276,000. Finally, State Street Corp lifted its stake in Puma Biotechnology by 17.0% in the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company’s stock worth $1,534,000 after purchasing an additional 87,504 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.